Cardiovascular diseases (CVD) remain the leading cause of disease burden , causing one in three deaths worldwide as a result of population growth, population aging and exposure to a broad range of ...

The ketogenic or “keto” diet, which involves consuming very low amounts of carbohydrates and high amounts of fats, has been gaining popularity. However, a new study presented at the American College ...

The Young Investigator Awards competition provides young scientific investigators with an opportunity to showcase their cutting-edge research. At ACC.27-WCC, 15 finalists will present their work in ...

Inflammation plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease. 1 Atherosclerosis in particular is an inflammatory process that involves endothelial dysfunction, ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond ...

In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

The ACC is dedicated to creating a strong, diverse and inclusive field of future cardiovascular physicians, scientists and professionals. The ACC's Internal Medicine and Pediatric Cardiology Program ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

Digitoxin is beneficial in reducing the combined risk of heart failure (HF) hospitalization and all-cause mortality in patients with systolic HF. Maintaining serum digitoxin levels in a narrow ...